{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:57:36Z","timestamp":1793861856722,"version":"4.6.1"},"reference-count":66,"publisher":"American Society for Clinical Investigation","issue":"17","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"crossref","award":["R01AR070470,K24AR063120"],"award-info":[{"award-number":["R01AR070470,K24AR063120"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"crossref","award":["P30AR075043"],"award-info":[{"award-number":["P30AR075043"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008456","name":"A. Alfred Taubman Medical Research Institute","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008456","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"crossref","award":["K01AR072129"],"award-info":[{"award-number":["K01AR072129"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Systemic sclerosis (SSc) is an autoimmune, connective tissue disease characterized by vasculopathy and fibrosis of the skin and internal organs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We randomized 15 participants with early diffuse cutaneous SSc to tofacitinib 5 mg twice a day or matching placebo in a phase I\/II double-blind, placebo-controlled trial. The primary outcome measure was safety and tolerability at or before week 24. To understand the changes in gene expression associated with tofacitinib treatment in each skin cell population, we compared single-cell gene expression in punch skin biopsies obtained at baseline and 6 weeks following the initiation of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Tofacitinib was well tolerated; no participants experienced grade 3 or higher adverse events before or at week 24. Trends in efficacy outcome measures favored tofacitnib. Baseline gene expression in fibroblast and keratinocyte subpopulations indicated IFN-activated gene expression. Tofacitinib inhibited IFN-regulated gene expression in SFRP2\/DPP4 fibroblasts (progenitors of myofibroblasts) and in MYOC\/CCL19, representing adventitial fibroblasts (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05), as well as in the basal and keratinized layers of the epidermis. Gene expression in macrophages and DCs indicated inhibition of STAT3 by tofacitinib (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). No clinically meaningful inhibition of T cells and endothelial cells in the skin tissue was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>These results indicate that mesenchymal and epithelial cells of a target organ in SSc, not the infiltrating lymphocytes, may be the primary focus for therapeutic effects of a Janus kinase inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT03274076.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>FUNDING<\/jats:title>\n                    <jats:p>Pfizer, NIH\/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R01 AR070470, NIH\/NIAMS K24 AR063120, Taubman Medical Research Institute and NIH P30 AR075043, and NIH\/NIAMS K01 AR072129.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1172\/jci.insight.159566","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T12:00:45Z","timestamp":1660046445000},"source":"Crossref","is-referenced-by-count":83,"title":["Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial"],"prefix":"10.1172","volume":"7","author":[{"given":"Dinesh","family":"Khanna","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, and"},{"name":"University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Padilla","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1627-5722","authenticated-orcid":true,"given":"Lam C.","family":"Tsoi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-3200","authenticated-orcid":true,"given":"Vivek","family":"Nagaraja","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, and"},{"name":"University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja P.","family":"Khanna","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, and"},{"name":"VA Medical Center, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Tabib","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-8945","authenticated-orcid":true,"given":"J. Michelle","family":"Kahlenberg","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Young","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suiyuan","family":"Huang","sequence":"additional","affiliation":[{"name":"University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA."},{"name":"Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann E.","family":"Gudjonsson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0230-6607","authenticated-orcid":true,"given":"David A.","family":"Fox","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-5034","authenticated-orcid":true,"given":"Robert","family":"Lafyatis","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30933-9"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270607"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI131700"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.027094"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-015-0554-8"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.167"},{"issue":"2","key":"B7","first-page":"318","article-title":"The mechanism of action of tofacitinib \u2014 an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-7-41"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173238"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12190"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/2397198319865367"},{"issue":"3","key":"B12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jdermsci.2020.12.007","article-title":"Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma","volume":"101","author":"Aung","year":"2020","journal-title":"J Dermatol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114103"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24607-6"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.27220"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.39287"},{"issue":"2","key":"B17","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4049\/jimmunol.159.2.794","article-title":"Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages","volume":"159","author":"Lehtonen","year":"1997","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202271"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/75556"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1055"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.03.011"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.03.032"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000827"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.06.020"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.440115"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030277"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.02.005"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.542829"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.38324"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040979"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-57507-8"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/srep39393"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2016.3575"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0344-8"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004251"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02981"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.08.012"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12519"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nature14362"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/art.41246"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M505839200"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150284"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/art.34649"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/art.34500"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02892-y"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214865"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/art.22382"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.200"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000659"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex280"},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00266","article-title":"The role of type 1 interferon in systemic sclerosis","volume":"4","author":"Wu","year":"2013","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20180250"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14532"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI74942"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00244.2018"},{"issue":"23\u201324","key":"B56","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1101\/gad.343129.120","article-title":"Senescence and the SASP: many therapeutic avenues","volume":"34","author":"Birch","year":"2020","journal-title":"Genes Dev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.593283"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0712-x"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-014-0473-0"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000219"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.646984"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201504-0780OC"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00235.2017"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/art.38098"},{"issue":"7","key":"B65","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.05.031"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/159566\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:30:32Z","timestamp":1779147032000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/159566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":66,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9,8]]},"published-print":{"date-parts":[[2022,9,8]]}},"alternative-id":["10.1172\/jci.insight.159566"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.159566","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"article-number":"e159566"}}